CN112961914A - miR-3074-5p作为类风湿关节炎标志物的应用及其试剂盒 - Google Patents
miR-3074-5p作为类风湿关节炎标志物的应用及其试剂盒 Download PDFInfo
- Publication number
- CN112961914A CN112961914A CN202110171439.0A CN202110171439A CN112961914A CN 112961914 A CN112961914 A CN 112961914A CN 202110171439 A CN202110171439 A CN 202110171439A CN 112961914 A CN112961914 A CN 112961914A
- Authority
- CN
- China
- Prior art keywords
- mir
- kit
- rheumatoid arthritis
- tnfsf14
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091047945 miR-3074 stem-loop Proteins 0.000 title claims abstract description 92
- 108091050163 miR-3074-1 stem-loop Proteins 0.000 title claims abstract description 92
- 108091055582 miR-3074-2 stem-loop Proteins 0.000 title claims abstract description 92
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 61
- 239000003550 marker Substances 0.000 title description 4
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 claims abstract description 39
- 102000012883 Tumor Necrosis Factor Ligand Superfamily Member 14 Human genes 0.000 claims abstract description 34
- 239000002679 microRNA Substances 0.000 claims abstract description 31
- 108091070501 miRNA Proteins 0.000 claims abstract description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 21
- 238000001514 detection method Methods 0.000 claims abstract description 20
- 108700011259 MicroRNAs Proteins 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000003147 molecular marker Substances 0.000 claims abstract description 5
- 239000003112 inhibitor Substances 0.000 claims description 20
- 238000010839 reverse transcription Methods 0.000 claims description 11
- 238000009007 Diagnostic Kit Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 239000011535 reaction buffer Substances 0.000 claims description 4
- 230000002441 reversible effect Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 abstract description 16
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 230000003334 potential effect Effects 0.000 abstract 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 238000003757 reverse transcription PCR Methods 0.000 description 12
- 239000005089 Luciferase Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 5
- 238000012761 co-transfection Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108090000331 Firefly luciferases Proteins 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000104 diagnostic biomarker Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 101100185408 Mus musculus Mug2 gene Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108091026822 U6 spliceosomal RNA Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003125 jurkat cell Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000009752 translational inhibition Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
名称 | 引物序列 | 序列号 |
TNFSF14 | 5'-ATACAAGAGCGAAGGTCTCACG-3'(F) | SEQ ID No.1 |
TNFSF14 | 5'-CTGAGTCTCCCATAACAGCGG-3'(R) | SEQ ID No.2 |
GAPDH | 5'-GGAGTCCACTGGCGTCTTC-3'(F) | SEQ ID No.3 |
GAPDH | 5'-GCTGATGATCTTGAGGCTGTTG-3'(R) | SEQ ID No.4 |
试剂组分 | 体积 | 终浓度 |
总RNA | 2-5μl | 可达2μg |
2×miRNA RT Reaction Buffer | 10μl | 1× |
miRNA RT Enzyme Mix | 2μl | - |
RNase-Free ddH<sub>2</sub>O | 补至20μl | - |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110171439.0A CN112961914B (zh) | 2021-02-07 | 2021-02-07 | miR-3074-5p作为类风湿关节炎标志物的应用及其试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110171439.0A CN112961914B (zh) | 2021-02-07 | 2021-02-07 | miR-3074-5p作为类风湿关节炎标志物的应用及其试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112961914A true CN112961914A (zh) | 2021-06-15 |
CN112961914B CN112961914B (zh) | 2022-08-30 |
Family
ID=76275416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110171439.0A Active CN112961914B (zh) | 2021-02-07 | 2021-02-07 | miR-3074-5p作为类风湿关节炎标志物的应用及其试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112961914B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101643730A (zh) * | 2009-07-27 | 2010-02-10 | 北京大学人民医院 | 微小RNA-146a在类风湿关节炎治疗中的用途 |
CN103805696A (zh) * | 2013-12-12 | 2014-05-21 | 焦志军 | 一种诊断类风湿关节炎的microRNA分子标志物及其检测试剂盒 |
US20140147454A1 (en) * | 2012-11-26 | 2014-05-29 | Moderna Therapeutics, Inc. | Terminally modified rna |
CN106492223A (zh) * | 2016-09-29 | 2017-03-15 | 哈尔滨医科大学 | microRNA‑34a‑5p抑制剂在制备治疗类风湿关节炎药物中的应用 |
US20180305689A1 (en) * | 2015-04-22 | 2018-10-25 | Mina Therapeutics Limited | Sarna compositions and methods of use |
-
2021
- 2021-02-07 CN CN202110171439.0A patent/CN112961914B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101643730A (zh) * | 2009-07-27 | 2010-02-10 | 北京大学人民医院 | 微小RNA-146a在类风湿关节炎治疗中的用途 |
US20140147454A1 (en) * | 2012-11-26 | 2014-05-29 | Moderna Therapeutics, Inc. | Terminally modified rna |
CN103805696A (zh) * | 2013-12-12 | 2014-05-21 | 焦志军 | 一种诊断类风湿关节炎的microRNA分子标志物及其检测试剂盒 |
US20180305689A1 (en) * | 2015-04-22 | 2018-10-25 | Mina Therapeutics Limited | Sarna compositions and methods of use |
CN106492223A (zh) * | 2016-09-29 | 2017-03-15 | 哈尔滨医科大学 | microRNA‑34a‑5p抑制剂在制备治疗类风湿关节炎药物中的应用 |
Non-Patent Citations (3)
Title |
---|
YAN GU ET AL.: ""Aberrant Placental Villus Expression of miR-486-3p" and miR-3074-5p in Recurrent Miscarriage Patients and Uterine Expression of These MicroRNAs during Early Pregnancy in Mice", 《GYNECOL OBSTET INVEST》 * |
ZHUYAN JIANG ET AL.: ""circPTPN22 as a novel biomarker and ceRNA in peripheral blood mononuclear cells of rheumatoid arthritis"", 《MOLECULAR MEDICINE REPORTS》 * |
蒋柱燕等: ""miR-3074-5p通过靶向TNFSF14参与类风湿关节炎的发生发展"", 《免疫学杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
CN112961914B (zh) | 2022-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Smigielska-Czepiel et al. | Comprehensive analysis of miRNA expression in T-cell subsets of rheumatoid arthritis patients reveals defined signatures of naive and memory Tregs | |
Nakasa et al. | Expression of microRNA‐146 in rheumatoid arthritis synovial tissue | |
Rossato et al. | Association of MicroRNA‐618 expression with altered frequency and activation of plasmacytoid dendritic cells in patients with systemic sclerosis | |
Ho et al. | MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2 | |
Hirota et al. | Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma | |
Kalpachidou et al. | Non-coding RNAs in neuropathic pain | |
Townsend | Molecular and cellular heterogeneity in the Rheumatoid Arthritis synovium: clinical correlates of synovitis | |
Zou et al. | Involvement of long noncoding RNAs in the pathogenesis of autoimmune diseases | |
Ibrahim et al. | Inflammatory gene networks in term human decidual cells define a potential signature for cytokine-mediated parturition | |
Gimondi et al. | Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation | |
WO2014014518A1 (en) | Methods for treating, preventing and predicting risk of developing breast cancer | |
Schena et al. | microRNAs in glomerular diseases from pathophysiology to potential treatment target | |
EP3933050A1 (en) | Application of circular rna in preparing drug for treating systemic lupus erythematosus | |
WO2015143062A1 (en) | Dux4-induced gene expression in facioscapulohumeral muscular dystrophy (fshd) | |
Jabandziev et al. | The emerging role of noncoding RNAs in pediatric inflammatory bowel disease | |
Tofigh et al. | Rheumatoid arthritis and non-coding RNAs; how to trigger inflammation | |
Qiu et al. | Comprehensive transcriptome analysis reveals competing endogenous RNA networks during avian leukosis virus, subgroup j-induced tumorigenesis in chickens | |
WO2013009705A2 (en) | Biomarkers, methods, and compositions for inhibiting a multi-cancer mesenchymal transition mechanism | |
CN112961914B (zh) | miR-3074-5p作为类风湿关节炎标志物的应用及其试剂盒 | |
CN113980968B (zh) | 一种新的ra标志长链非编码rna及其应用 | |
Romero et al. | Primary mediastinal large B-cell lymphoma: Transcriptional regulation by miR-92a through FOXP1 targeting | |
CN112795640B (zh) | 三种microRNA作为RA标志物的应用及其试剂盒 | |
CN102899405A (zh) | 检测肺癌肿瘤细胞rna变化的试剂盒 | |
CN111534587A (zh) | 分子标志物5-tRF-His、乳腺癌检测试剂盒及其应用 | |
Wang et al. | MicroRNA‐7 deficiency ameliorates d‐galactose‐induced aging in mice by regulating senescence of Kupffer cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240110 Address after: 230000 No.9 Lujiang Road, Luyang District, Hefei City, Anhui Province Patentee after: Anhui Provincial Hospital (the First Affiliated Hospital of China University of science and Technology) Address before: 230000 No.9 Lujiang Road, Luyang District, Hefei City, Anhui Province Patentee before: Anhui Provincial Hospital (the First Affiliated Hospital of China University of science and Technology) Patentee before: THIRD MILITARY MEDICAL University |
|
TR01 | Transfer of patent right |